BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11722420)

  • 21. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.
    Kunitomi A; Arima N; Ishikawa T
    Haematologica; 2007 Apr; 92(4):e49-52. PubMed ID: 17562592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.
    Muramatsu H; Takahashi Y; Shimoyama Y; Doisaki S; Nishio N; Ito Y; Hama A; Shimada A; Yagasaki H; Ito M; Kojima S
    Int J Hematol; 2011 Jun; 93(6):779-781. PubMed ID: 21559814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
    Comoli P; Basso S; Zecca M; Pagliara D; Baldanti F; Bernardo ME; Barberi W; Moretta A; Labirio M; Paulli M; Furione M; Maccario R; Locatelli F
    Am J Transplant; 2007 Jun; 7(6):1648-55. PubMed ID: 17511690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of post-transplant lymphoproliferative disease with rituximab].
    Jiang YJ; Wang X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):852-6. PubMed ID: 24989308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
    Seshadri M; Crane GM; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):68-73. PubMed ID: 32413419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.
    Savoldo B; Rooney CM; Quiros-Tejeira RE; Caldwell Y; Wagner HJ; Lee T; Finegold MJ; Dotti G; Heslop HE; Goss JA
    Am J Transplant; 2005 Mar; 5(3):566-72. PubMed ID: 15707412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Li JP; Zhang T; Zhong J; Chen J
    Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.
    Herman J; Vandenberghe P; van den Heuvel I; Van Cleemput J; Winnepenninckx V; Van Damme-Lombaerts R
    J Heart Lung Transplant; 2002 Dec; 21(12):1304-9. PubMed ID: 12490276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
    Xu LP; Liu DH; Liu KY; Zhang CL; Wang FR; Wang JZ; Wang Y; Chen H; Zhang YY; Yan CH; Han W; Chen YH; Zhao T; Zhang XH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
    Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
    Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
    Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.